Salud financiera de hoja de balance de Alembic Pharmaceuticals
Salud financiera controles de criterios 6/6
Alembic Pharmaceuticals tiene un patrimonio de accionistas total de ₹44.7B y una deuda total de ₹8.7B, lo que sitúa su ratio deuda-patrimonio en 19.4%. Sus activos y pasivos totales son ₹64.6B y ₹19.9B respectivamente. El BAIT de Alembic Pharmaceuticals es de ₹6.1B, por lo que su ratio de cobertura de intereses es de 10.3. Tiene efectivo e inversiones a corto plazo que ascienden a ₹1.5B.
Información clave
8.9%
Ratio deuda-patrimonio
₹4.30b
Deuda
| Ratio de cobertura de intereses | 12.3x |
| Efectivo | ₹1.27b |
| Patrimonio | ₹48.18b |
| Total pasivo | ₹16.27b |
| Activos totales | ₹64.46b |
Actualizaciones recientes sobre salud financiera
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Recent updates
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jan 17Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?
Dec 17These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well
Sep 23Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?
Sep 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹31.3B) de APLLTD superan a sus pasivos a corto plazo (₹18.1B).
Pasivo a largo plazo: Los activos a corto plazo de APLLTD (₹31.3B) superan a sus pasivos a largo plazo (₹1.8B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (16.1%) de APLLTD se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de APLLTD ha pasado de 44.7% a 19.4% en los últimos 5 años.
Cobertura de la deuda: La deuda de APLLTD está bien cubierta por el flujo de caja operativo (69.4%).
Cobertura de intereses: Los pagos de intereses de la deuda de APLLTD están bien cubiertos por el BAIT (10.3x cobertura).